Leerink Partnrs lowered shares of iTeos Therapeutics (NASDAQ:ITOS - Free Report) from a strong-buy rating to a hold rating in a report published on Wednesday,Zacks.com reports. Leerink Partnrs also issued estimates for iTeos Therapeutics' Q4 2025 earnings at ($0.38) EPS and FY2029 earnings at ($1.78) EPS.
A number of other brokerages have also recently issued reports on ITOS. JPMorgan Chase & Co. cut shares of iTeos Therapeutics from an "overweight" rating to a "neutral" rating and reduced their price objective for the company from $15.00 to $8.00 in a research note on Tuesday, May 13th. Raymond James set a $12.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday. Piper Sandler reaffirmed an "overweight" rating and issued a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday. HC Wainwright cut shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday. Finally, Leerink Partners reissued a "market perform" rating and set a $9.00 price target (down from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $17.86.
Check Out Our Latest Research Report on ITOS
iTeos Therapeutics Stock Down 2.0%
ITOS stock traded down $0.16 during midday trading on Wednesday, reaching $7.81. The company's stock had a trading volume of 1,321,488 shares, compared to its average volume of 546,662. iTeos Therapeutics has a 52 week low of $4.80 and a 52 week high of $18.70. The stock has a market cap of $298.92 million, a PE ratio of -2.48 and a beta of 1.39. The business's 50-day simple moving average is $6.61 and its 200-day simple moving average is $7.41.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14. As a group, equities analysts forecast that iTeos Therapeutics will post -3.49 earnings per share for the current fiscal year.
Insider Transactions at iTeos Therapeutics
In related news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the firm's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the sale, the insider now directly owns 3,452,797 shares in the company, valued at $27,829,543.82. This trade represents a 23.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the firm's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the sale, the insider now owns 2,108,594 shares in the company, valued at approximately $16,995,267.64. The trade was a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 12.50% of the company's stock.
Institutional Investors Weigh In On iTeos Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in ITOS. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of iTeos Therapeutics during the fourth quarter worth $42,000. CWM LLC raised its holdings in shares of iTeos Therapeutics by 428.7% during the first quarter. CWM LLC now owns 8,554 shares of the company's stock worth $51,000 after acquiring an additional 6,936 shares during the period. Paloma Partners Management Co acquired a new stake in iTeos Therapeutics in the 1st quarter valued at $65,000. Dynamic Technology Lab Private Ltd acquired a new stake in iTeos Therapeutics in the 1st quarter valued at $67,000. Finally, Virtus ETF Advisers LLC increased its stake in iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock valued at $69,000 after buying an additional 3,293 shares during the last quarter. 97.16% of the stock is currently owned by institutional investors and hedge funds.
About iTeos Therapeutics
(
Get Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Recommended Stories
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
